«The results of the phase III clinical trial
show that a target fusion biopsy detects more clinically significant prostate cancer,» said Art Rastinehad, DO, principal investigator of the study and director of interventonal
urologic oncology at North Shore - LIJ's Arthur Smith Institute for Urology, in New Hyde Park, NY.